MedTrace Logo

The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients

NCT06173817 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-02-11

No results posted yet for this study

Summary

The projects investigate if treatment with isocapnic hyperventilation can eliminate methanol from the body in a similar manner to dialysis. This is achieved by administering the antidote (fomepizole) and let the patient breathe on a isocapnic hyperventilation device while samples of blood, urine and maybe the breath are collected to measure the contents of methanol and its metabolites.

Conditions

  • Methanol Poisoning

Interventions

DEVICE

isocapnic hyperventilation

isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.

Sponsors & Collaborators

  • Loghman-Hakim Hospital, Teheran, Iran

    collaborator UNKNOWN

  • Shohada-e-Tajrish Hospital, Teheran, Iran

    collaborator UNKNOWN

  • Baharloo Hospital, Teheran, Iran

    collaborator UNKNOWN

  • Imam Reza Hospital, Mashhad University of Medical Sciences, Iran

    collaborator UNKNOWN

  • Khorshid Hospital, Isfahan University of Medical Sciences, Iran

    collaborator UNKNOWN

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Knut Erik Hovda, MD, Ph D · The Norwegian CBRNE Centre, Department of Acute Medicine, Oslo University Hospital Oslo, Norway

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-29
Primary Completion
2026-01-29
Completion
2026-01-29

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173817 on ClinicalTrials.gov